Amphastar Pharmaceuticals, Inc.

Form 4

August 19, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Gerst Diane G.

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Amphastar Pharmaceuticals, Inc.

(Check all applicable)

[AMPH]

(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 08/19/2016

Director 10% Owner Other (specify X_ Officer (give title below)

C/O AMPHASTAR PHARMACEUTICALS,

CUCAMONGA, CA 91730

INC., 11570 6TH STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

EVP, QA & Regulatory Affairs

Applicable Line)

RANCHO

X Form filed by One Reporting Person Form filed by More than One Reporting

| (City) | (State) | (Zip) Table | e I - Non-D | erivative S | Securi | ties Acqu | ired, Disposed of | or Beneficiall | y Owned |
|--------------------------------------|--------------------------------------|---|--|-------------------------------------|--------|-------------|--|--|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transactio Code (Instr. 8) | 4. Securitin(A) or Dis (Instr. 3, 4 | sposed | of (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock | 08/19/2016 | | M | 10,046 | A | \$ 14.23 | 39,031 | D | |
| Common Stock | 08/19/2016 | | M | 14,000 | A | \$ 10.93 | 53,031 | D | |
| Common Stock | 08/19/2016 | | S <u>(1)</u> | 24,046 | D | \$ 19.28 | 28,985 | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | |
|---|---|---|---|---|---|--|--------------------|---|-------------------------------------|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Employee Stock Option (right to buy) | \$ 14.23 | 08/19/2016 | | M | 10,046 | (2) | 12/22/2021 | Common Stock | 10,046 |
| Employee Stock Option (right to buy) | \$ 10.93 | 08/19/2016 | | M | 14,000 | (2) | 07/30/2023 | Common Stock | 14,000 |

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

EVP, QA & Regulatory Affairs

Gerst Diane G.

C/O AMPHASTAR PHARMACEUTICALS, INC.

11570 6TH STREET

RANCHO CUCAMONGA, CA 91730

Signatures

/s/ Ken Stupak, by power of attorney

08/19/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2016.

Reporting Owners 2

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

(2) Shares subject to the option are fully vested and immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.